By Torpedo / 27th January, 2026
Swiss Rockets AG to Sponsor and Participate with an Exhibition Booth at the 8th Theranostics World Congress 2026 in Cape Town
Basel, Switzerland, January 27, 2026 - Swiss Rockets AG, will participate as a sponsor at the 8th Theranostics World Congress (TWC) 2026, the leading international forum for nuclear medicine and radiomolecular precision oncology. In addition to sponsoring the congress, Swiss Rockets will be present with an exhibition booth and an official presentation introducing the Swiss Rockets Group and its operating model.
During the congress, Dr. Vladimir Cmiljanovic, CEO of Swiss Rockets AG, will present the Group’s incubator and accelerator approach, outlining how Swiss Rockets identifies, builds, and advances specialized biotechnology companies from early scientific innovation through clinical development. The presentation will also introduce Swiss Rockets’ subsidiaries and their strategic focus areas.
Swiss Rockets is actively engaged in the field of radioligand therapies (RLTs) through its subsidiaries Torpedo Pharmaceuticals AG and Rocket Isotopes AG. Torpedo Pharmaceuticals is developing next-generation radioligand therapies based on Terbium-161, while Rocket Isotopes is building the associated isotope production and supply infrastructure. Together, they represent Swiss Rockets’ integrated approach to advancing radiomolecular precision oncology.
Beyond its existing portfolio, Swiss Rockets continues to explore new scientific and strategic opportunities within the RLT ecosystem, including collaborations, technology platforms, and early-stage innovations aligned with theranostics and precision medicine.
Swiss Rockets AG welcomes discussions with scientific partners, clinicians, and industry stakeholders throughout the congress. Visit us at our booth at the Theranostics World Congress 2026.